Skip to content

Screening and Identification of Human Urate Transporter hURAT1 MicroRNA

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01973088
Enrollment
80
Registered
2013-10-31
Start date
2013-11-30
Completion date
Unknown
Last updated
2013-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Calculi

Brief summary

This study intends to use in patients with renal tissue and blood samples, screening and identification of renal tissue hURAT1 regulating the expression of micro-RNA, for further study of uric acid stone formation mechanism and the occurrence of clinical preventive uric acid stones provide new clues and new intervention targets.

Interventions

None listed

Sponsors

Qian-wei Li
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

A、B group were enrolled standards: ① aged 18-65 years old; ② comply with percutaneous nephrolithotomy lithotripsy indications for surgery; ③ ECT tips ipsilateral normal or mildly impaired renal function. Group C patients were enrolled standards: ① aged 18-65 years old; ② normal renal function, not associated with urinary calculi in patients; ③ cancer patients met radical nephrectomy indications for surgery; ④ emergency trauma patients suffering from kidney resection surgical indications.

Exclusion criteria

* aged \<18 years or\> 65 years; ② neurological disease or cognitive dysfunction; ③ can not be corrected or uncorrected coagulopathy; ④ associated with diabetes, hypertension and other metabolic diseases; ⑤ accompanied by tuberculosis, hepatitis, HIV and other infectious diseases; ⑥ poor tolerance to anesthesia and surgery, such as: severe cardiopulmonary disease, coagulation disorders, etc.; ⑦ ultrasound, renal imaging examination revealed renal cortex was significantly thinner (renal cortical thickness \<1.5cm), structural variation; ⑧ with severe systemic or urinary tract infection; ⑨ ECT tips ipsilateral renal function is severely impaired or solitary kidney.

Design outcomes

Primary

MeasureTime frameDescription
micro-RNA6 monthsmicroRNA microarray:the micro-RNA of kidney tissue

Secondary

MeasureTime frameDescription
Urine24 hoursUrine Analyzer:Urine color, transparency, pH, erythrocytes, leukocytes, epithelial cells, casts, protein, specific gravity, and qualitative urine
24h urine quantitative analysis96 hoursUrine Analyzer:Urine, sodium, potassium, calcium, magnesium, ammonium, phosphate, sulfate, uric acid, oxalate, citrate, creatinine
Blood biochemistry24 hoursBlood biochemical analyzer:Sodium, potassium, chloride, calcium, phosphorus, magnesium, bicarbonate, uric acid, creatinine
Stone analysis3 weeksInfrared Spectroscopy:Calcium oxalate monohydrate , carbonated apatite, calcium oxalate dihydrate ,anhydrous uric acid, urine ammonium,magnesium ammonium phosphate
hURAT1 transporter protein6 monthsWESTERN BLOT、RT-qPCR:hURAT1 transporter protein of kidney tissue

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026